MARINA KVASKOFF

 

▪ 2022-2024 : Persistent organic pollutants and endometriosis: a metabolomic association study (EndoxOmics), Fondation pour la Recherche Médicale (542 k€). Rôle: Co-I (PI: G. CANO-SANCHO, INRAE)

▪ 2020-2024 : Genetic variants, early life exposures, and longitudinal endometriosis symptoms study (GELLES), Australian Ministry of Health, Medical Research Future Fund (AUD $1,86M soit ~1,13 M€). Rôle : Co-I (PI : G. MISHRA, The University of Queensland)


▪ 2020-2022 : Vitamin D and melanoma risk and survival in the European EPIC cohort (MELVITAD), Institut National du Cancer (458 k€). Rôle : PI


▪ 2019-2021 : The impact of comorbidity on cancer detection and survival (ComoCanS), Institut National du Cancer (80 k€). Rôle : Co-I (PI : H. FREISLING, International Agency for Research on Cancer)

▪ 2017-2020 : Endocrine disrupting chemicals and risk of hormone-related cancers: the E3N prospective cohort (ED-CANCER), Inserm (637 k€). Rôle : PI

▪ 2017-2020 : Health of cancer survivors: Fundamental knowledge from large French cohorts for the development of a tertiary prevention strategy in oncology (AFTER-CANCER), Fondation ARC, Institut National du Cancer (INCa) et Institut de Recherche en Santé Publique (IReSP) (634 k€). Rôle : PI

▪ 2017 : Confirmation and refinement of the model of heterogeneity for cutaneous melanoma in the European EPIC cohort: a pilot study (HETEROMEL), Ligue Contre le Cancer (60 k€). Rôle : PI

▪ 2015-2018 : Sex steroid hormones and melanoma risk and survival in the European EPIC cohort (H-MELA), Institut National du Cancer (381 k€). Rôle : PI

▪ 2012-2015 : Epidemiological investigation into the association between endometriosis and cutaneous melanoma (MELENDO2), Marie Curie Fellowship, Commission européenne (269 k€). Rôle : PI

▪ 2010-2013 : Genetic factors, pigmentary phenotype, sun exposure and skin cancer risk in the E3N cohort (MELAGEN), Institut National du Cancer (237 k€). Rôle : PI